key Figures
 | 22,500 employees |
 | 98% of Servier brand-name medicinesactive ingredients are synthesized in France. |
 | 150 countriesin which the Group’s medicines are distributed |
 | 4 therapeutic areasoncology, cardiometabolism, neuroscience and immuno-inflammation |
 | 36 projectsin clinical development, including 26 new molecular entities (May 2021). |
 | A strong international presence96% of Group revenue (from brand-name medicines) generated outside France. |
| | 16 chemical and pharmaceutical production sites |
 | 15 International Centers for Therapeutic Researchand 5 R&D centers (2 in France, 1 in Denmark, 1 in Hungary and 1 in the US). |
 | €4.7 billion euros in revenuecomprising €3.3 billion for brand-name medicines and €1.4 billion for generic medicines. |
 | 23% of revenue from brand-name medicines invested in R&Din 2019/2020 |
 | 31st largest pharmaceutical Group worldwideand 2nd largest pharmaceutical Group in France[1]. |
 | A leader position in cardiology in France3rd leading pharmaceutical Group worldwide[1]. |
 | Participation reached 36% of the trade balance surplus in Francein pharmaceuticals and fine chemicals (brand-name medicines), amounting to €1.6 billion. |
Key figures as of September 30th, 2020
[1] Source: IQVA, Analytics Link – MAT Q1 2021